Cardinal Analytx, Inc.

Cardinal Analytx, Inc. leverages advanced predictive analytics to enhance healthcare decision-making, helping organizations transition from reactive to proactive healthcare management. Founded in 2013, Cardinal Analytx, Inc. is based in Palo Alto, US, focusing on predictive analytics in healthcare.

The company has raised a total of USD 20. 63 mn through its Series B funding round on March 22, 2019, led by investors such as Blue Shield of California and GuideWell, with participation from Premera Blue Cross. The firm has completed a total of 2 deals since inception, with a current company valuation of USD 56. 89 mn.

The firm is co-led by CEOs Kyle Raffaniello and Linda Hand. Cardinal Analytx offers advanced predictive analytics solutions in healthcare, primarily through its MetisAI model. This state-of-the-art foundation model aims to revolutionize healthcare practices by proactively predicting members' future health events, their timing, and potential costs. By utilizing a self-supervised transformer pre-trained on extensive datasets, the MetisAI model targets healthcare payers, providers, and organizations in North America to enhance financial risk management and improve patient outcomes.

The company operates on a subscription-based revenue model, providing its predictive analytics services to healthcare organizations and insurers. Cardinal Analytx engages clients through partnerships involving tiered pricing structures based on service utilization. The MetisAI model, along with other analytics tools, forms the core of its offerings, which are typically structured around annual or multi-year contracts, allowing seamless integration into existing systems for real-time decision-making. Cardinal Analytx plans to leverage its USD 20.

63 mn funding from the Series B round in March 2019 to enhance its predictive analytics capabilities and expand its market presence. The company aims to develop new products designed to increase the accuracy and efficiency of its existing offerings while targeting growth in specific markets within North America. Through strategic partnerships and innovative product launches, Cardinal Analytx intends to broaden its reach, catering to a larger clientele in both fully insured and self-funded healthcare sectors.